NDAORALTABLET
Approved
Oct 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THIOSULFIL (sulfamethizole) is an oral sulfonamide antibiotic approved in 1953 for bacterial infections. The drug belongs to the sulfonamide class and works by inhibiting bacterial folic acid synthesis. It is administered as a tablet for systemic treatment of susceptible gram-positive and gram-negative infections.
LOE Approaching
Product is in advanced lifecycle stage with minimal market presence; brand team likely focused on retention rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on THIOSULFIL offers limited career advancement opportunities given its LOE status and minimal commercial momentum. Roles are primarily focused on compliance, safety surveillance, and managing a declining patient base rather than growth or innovation.
Product Manager (Legacy/Maintenance)Regulatory Affairs Specialist
Worked on THIOSULFIL at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.